These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33376376)

  • 81. A Novel Multi-Action Emollient Plus Cream Improves Skin Barrier Function in Patients with Atopic Dermatitis: In vitro and Clinical Evidence.
    Quadri M; Lotti R; Bonzano L; Ciardo S; Guanti MB; Pellacani G; Pincelli C; Marconi A
    Skin Pharmacol Physiol; 2021; 34(1):8-18. PubMed ID: 33601378
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [Optimization of emollient formulation for treating atopic dermatitis by skin physiological index testing].
    Huang SG; Yang XX; Mo LQ; Zhou XY
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jul; 37(7):967-974. PubMed ID: 28736378
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity.
    Chamlin SL; Kao J; Frieden IJ; Sheu MY; Fowler AJ; Fluhr JW; Williams ML; Elias PM
    J Am Acad Dermatol; 2002 Aug; 47(2):198-208. PubMed ID: 12140465
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Best emollients for eczema (BEE) - comparing four types of emollients in children with eczema: protocol for randomised trial and nested qualitative study.
    Ridd MJ; Wells S; Edwards L; Santer M; MacNeill S; Sanderson E; Sutton E; Shaw ARG; Banks J; Garfield K; Roberts A; Barrett TJ; Baxter H; Taylor J; Lane JA; Hay AD; Williams HC; Thomas KS
    BMJ Open; 2019 Nov; 9(11):e033387. PubMed ID: 31699751
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Current concepts in the prevention of atopic dermatitis.
    Boulos S; Yan AC
    Clin Dermatol; 2018; 36(5):668-671. PubMed ID: 30217281
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients.
    Hon KL; Pong NH; Wang SS; Lee VW; Luk NM; Leung TF
    Drugs R D; 2013 Mar; 13(1):37-42. PubMed ID: 23456759
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Clinical and confocal evaluation of avenanthramides-based daily cleansing and emollient cream in pediatric population affected by atopic dermatitis and xerosis.
    Diluvio L; Dattola A; Cannizzaro MV; Franceschini C; Bianchi L
    G Ital Dermatol Venereol; 2019 Feb; 154(1):32-36. PubMed ID: 30207438
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Emollient formulations containing antiseptics reduce effectively the level of
    Spada F; Barnes TM; Greive KA
    Clin Cosmet Investig Dermatol; 2019; 12():639-645. PubMed ID: 31564945
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis.
    Kircik L
    J Drugs Dermatol; 2010 Apr; 9(4):334-8. PubMed ID: 20514790
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cost-effectiveness of Prophylactic Moisturization for Atopic Dermatitis.
    Xu S; Immaneni S; Hazen GB; Silverberg JI; Paller AS; Lio PA
    JAMA Pediatr; 2017 Feb; 171(2):e163909. PubMed ID: 27918774
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis.
    Maloney JM; Morman MR; Stewart DM; Tharp MD; Brown JJ; Rajagopalan R
    Int J Dermatol; 1998 Feb; 37(2):142-4. PubMed ID: 9542676
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Skin barrier breakdown: a renaissance in emollient therapy.
    Cork MJ; Danby S
    Br J Nurs; 2009 Jul 23-Aug 12; 18(14):872, 874, 876-7. PubMed ID: 19633599
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
    Shih YT; Cortes JE; Kantarjian HM
    Lancet Haematol; 2019 Aug; 6(8):e398-e408. PubMed ID: 31208943
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Real-World Evidence of an Emollient Device for Atopic and Contact Dermatitis in Pediatric to Adult Patients - Data from a Post-Marketing Surveillance.
    Hebert AA
    Clin Cosmet Investig Dermatol; 2022; 15():1797-1803. PubMed ID: 36101562
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Current treatments for atopic dermatitis in Japan.
    Miyano K; Tsunemi Y
    J Dermatol; 2021 Feb; 48(2):140-151. PubMed ID: 33377547
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Hidradenitis suppurativa and atopic dermatitis: A 2-way association.
    Sherman S; Kridin K; Bitan DT; Leshem YA; Hodak E; Cohen AD
    J Am Acad Dermatol; 2021 Dec; 85(6):1473-1479. PubMed ID: 33378660
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Emollients "Plus" are Beneficial in Both the Short and Long Term in Mild Atopic Dermatitis.
    Cestari S; Correia P; Kerob D
    Clin Cosmet Investig Dermatol; 2023; 16():2093-2102. PubMed ID: 37575149
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis.
    Cabout E; Eymere S; Launois R; Séité S; Delvigne V; Taïeb C; Reguai Z
    Acta Derm Venereol; 2021 Jul; 101(7):adv00509. PubMed ID: 34230978
    [TBL] [Abstract][Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.